Stockscreener 앱 받기
3.18
4.50%
-0.15
시간 외 거래:
3.19
0.010
+0.31%
Checkpoint Therapeutics Inc 주식(CKPT)의 최신 뉴스
Short Interest in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Increases By 17.5% - MarketBeat
Reviewing LifeVantage (NASDAQ:LFVN) & Checkpoint Therapeutics (NASDAQ:CKPT) - Defense World
Checkpoint Therapeutics (NASDAQ:CKPT) Coverage Initiated by Analysts at D. Boral Capital - Defense World
Checkpoint Therapeutics stock initiated at Buy Rating by Borak Capital - Investing.com Canada
This PG&E Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
D. Boral Capital Initiates Coverage on Checkpoint Therapeutics (NASDAQ:CKPT) - MarketBeat
D. Boral Capital Initiates Coverage of Checkpoint Therapeutics (CKPT) with Buy Recommendation - MSN
Checkpoint Therapeutics CFO signs new executive agreement By Investing.com - Investing.com Australia
Checkpoint Therapeutics CFO signs new executive agreement - Investing.com India
Geode Capital Management LLC Buys 124,787 Shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) - Defense World
Checkpoint Therapeutics Signs Executive Agreement with CFO - TipRanks
Checkpoint Therapeutics Inc (NASDAQ: CKPT) Today’s Hot Stock - Stocks Register
State Street Corp Grows Stock Holdings in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) - Defense World
Head to Head Contrast: Tyra Biosciences (NASDAQ:TYRA) and Checkpoint Therapeutics (NASDAQ:CKPT) - Defense World
Checkpoint Therapeutics CFO sells $1.08 million in stock - Investing.com India
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CFO Sells 268,432 Shares - MarketBeat
James F. Oliviero III Sells 220,230 Shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Stock - MarketBeat
Checkpoint Therapeutics CFO sells $1.08 million in stock By Investing.com - Investing.com Canada
Checkpoint Therapeutics CEO sells $3.07 million in stock By Investing.com - Investing.com Canada
Checkpoint Therapeutics: Updating My Strategy After Unloxcyt's Approval (NASDAQ:CKPT) - Seeking Alpha
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT for Treatment of Advanced Cutaneous Squamous Cell Carcinoma - Defense World
Biotech Alert: Searches spiking for these stocks today - TipRanks
Affimed Shares Fall 32% on Clinical Update - Yahoo Finance
Fortress Biotech subsidiary gains FDA approval for cSCC therapy - Investing.com
Soligenix initiates confirmatory Phase 3 trial of HyBryte - Yahoo Finance
Checkpoint Therapeutics (NASDAQ:CKPT) Receives Buy Rating from HC Wainwright - Defense World
Checkpoint Therapeutics (NASDAQ:CKPT) Price Target Raised to $7.00 at Lake Street Capital - Defense World
FDA Tracker: Neurocrine, Checkpoint Score FDA Approvals - BioSpace
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Short Interest Up 9.0% in November - MarketBeat
Investors Purchase Large Volume of Call Options on Checkpoint Therapeutics (NASDAQ:CKPT) - MarketBeat
FDA Approves Cosibelimab for Cutaneous SCC - Medscape
Checkpoint Therapeutics (NASDAQ:CKPT) Price Target Raised to $7.00 - MarketBeat
FDA Approves Checkpoint Therapeutics' Skin Cancer Drug One Year After Rejection - Yahoo Finance
HC Wainwright Reaffirms Buy Rating for Checkpoint Therapeutics (NASDAQ:CKPT) - MarketBeat
US Stocks To Open Higher Ahead Of Fed's Decision This Week: Analyst Says 'Santa Comes Later In December' - Benzinga
FDA approves Checkpoint Thera’s Unloxcyt - The Pharma Letter
Pre-market Movers: EWTX, TNXP, LNSR, VRDN... - RTTNews
Checkpoint stock on watch after FDA nod (CKPT:NASDAQ) - Seeking Alpha
Checkpoint Therapeutics' Shares Rise After Securing First FDA Approval - Marketscreener.com
Checkpoint Therapeutics Gets Its First FDA Approval - Marketscreener.com
US FDA approves Checkpoint's skin cancer drug - Reuters.com
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl) - GlobeNewswire
Checkpoint Therapeutics Secures First FDA Approval for Novel Cancer Drug UNLOXCYT in $1B+ Market - StockTitan
Absci highlights progress, updates across proprietary pipeline - Yahoo Finance
Lucid Group Inc (LCID-Q) QuotePress Release - The Globe and Mail
Nine PDUFA dates on FDA’s December calendar - BioCentury
Biotech Advances Drive Cancer Research as Global Rates Continue Upward Trend - cnhinews.com
Amazon.com Inc (AMZN-Q) QuotePress Release - The Globe and Mail
Checkpoint Therapeutics stock hits 52-week high at $3.98 By Investing.com - Investing.com South Africa
Checkpoint Therapeutics stock hits 52-week high at $3.98 - Investing.com
0.65%
4.62%
자본화:
|
볼륨(24시간):